Spero Therapeutics, Inc. (SPRO)
2.605
+0.02
(+0.97%)
USD |
NASDAQ |
May 19, 13:59
Spero Therapeutics Research and Development Expense (Quarterly) : 2.909M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| SELLAS Life Sciences Group, Inc. | 5.129M |
| Lantern Pharma, Inc. | 1.725M |
| ACADIA Pharmaceuticals, Inc. | 76.87M |
| Alnylam Pharmaceuticals, Inc. | 364.87M |
| Amgen, Inc. | 1.719B |